Education
About Us
Working with TipRanks
Follow Us
Cannabix Technologies Inc (TSE:BLO)
:BLO
BLO Stock Chart & Stats
C$0.60
-C$0.02(-4.76%)
At close: 4:00 PM EST
C$0.60
-C$0.02(-4.76%)
Day’s Range― - ―
52-Week RangeC$0.45 - C$0.68
Previous CloseN/A
Volume15.24K
Average Volume (3M)36.45K
Market Cap
C$61.75M
Enterprise ValueC$60.79M
Total Cash (Recent Filing)C$1.60M
Total Debt (Recent Filing)C$88.43K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding121,074,104
10 Day Avg. Volume30,616
30 Day Avg. Volume36,452
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)27.07
Price to Sales (P/S)0.00
P/FCF Ratio-37.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Limited DebtReported minimal debt and a ~0.05x debt-to-equity ratio lower near-term solvency risk and provide financing flexibility. For a pre-commercial med-device developer, low leverage preserves optionality for R&D, partnerships, or non-dilutive funding, extending runway vs high-debt peers.
Clear Product Focus & Addressable MarketsFocused strategy on breath-based cannabis and alcohol detection targets multiple durable end markets (workplace, law enforcement, personal). A clear product-market fit across regulatory and institutional buyers increases long-term commercialization pathways if technology and approvals progress.
Ongoing R&D And Device Engineering CapabilitySustained in-house R&D in breath collection, sample analysis and device engineering suggests development of technical know-how and potential IP. This capability is a durable asset enabling iterative improvements, regulatory submissions, and differentiation critical for med-device commercialization.
Bears Say
Minimal Revenue; Deep LossesExtremely low trailing revenue and large operating losses show the company has not achieved commercial scale. Persistent unprofitability limits internal funding for commercialization, increases reliance on external capital, and raises execution risk over the medium term if product monetization lags.
Sustained Negative Cash FlowRecurring negative operating and free cash flow (~-$2.0M TTM) represent ongoing cash burn. This structural cash deficit forces repeated financing or partnerships, risks dilution, and constrains investment in regulatory approvals, manufacturing scale-up, and commercial rollout without material revenue improvement.
Declining Equity And Negative ReturnsMaterial erosion of shareholder equity and strongly negative ROE reflect cumulative losses and likely dilution. A weakened capital base reduces the firm's ability to self-fund critical certification or manufacturing investments, making future financing more dilutive or difficult to secure.
Cannabix Technologies News
BLO FAQ
What was Cannabix Technologies Inc’s price range in the past 12 months?
Cannabix Technologies Inc lowest stock price was C$0.45 and its highest was C$0.68 in the past 12 months.
What is Cannabix Technologies Inc’s market cap?
Cannabix Technologies Inc’s market cap is C$61.75M.
When is Cannabix Technologies Inc’s upcoming earnings report date?
Cannabix Technologies Inc’s upcoming earnings report date is Mar 25, 2026 which is in 9 days.
How were Cannabix Technologies Inc’s earnings last quarter?
Cannabix Technologies Inc released its earnings results on Dec 30, 2025. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Cannabix Technologies Inc overvalued?
According to Wall Street analysts Cannabix Technologies Inc’s price is currently Overvalued.
Does Cannabix Technologies Inc pay dividends?
Cannabix Technologies Inc does not currently pay dividends.
What is Cannabix Technologies Inc’s EPS estimate?
Cannabix Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cannabix Technologies Inc have?
Cannabix Technologies Inc has 121,074,104 shares outstanding.
What happened to Cannabix Technologies Inc’s price movement after its last earnings report?
Cannabix Technologies Inc reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cannabix Technologies Inc?
Currently, no hedge funds are holding shares in TSE:BLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cannabix Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.02%
12-Months-Change
Fundamentals
Return on Equity
-259.71%
Trailing 12-Months
Asset Growth
-41.52%
Trailing 12-Months
Company Description
Cannabix Technologies Inc
Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, governments, and public in North America. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for the rapid detection of recent cannabis use, as well as breath collection units. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.
Technical Analysis
Imagin Medical
―
Perimeter Medical Imaging AI
―
Quipt Home Medical
―
VentriPoint Diagnostics
―
―
Options Prices
Currently, No data available
---